Ann: Anteris to Present at Cantor Healthcare Conference, page-60

First 60 Last

Share
Profile

Follow
asxunsullied

1,619 Posts.

189

22/09/23

19:40

Post #: 69986308
Share

Originally posted by synaphai: ↑

Massive amounts of capital must be raised to get new drugs and medical devices through the years of trials needed prove safety and efficacy. That capital can either come from investors or from taxpayers but given the high amount of failures among drugs and to a lesser extent devices, it's probably way too much risk for taxpayers to stomach.

$400 million will likely be spent getting the DurAVR to commercialization. That money has to come from somewhere with the vast majority of it in the form of issued shares. Public markets work for clinical stage companies because they match investors who have a significant appetite for risk with companies that may someday offer huge rewards. That's why we are all here.

The great part is that there are many hundreds of publicly traded clinical stage companies all over the world so we can choose which ones we want to invest in and size our positions accordingly depending on our individual assessments of risk and projections of future dilution. I've researched well over 200 and am currently in 5, including AVR.

Expand

sure 100% agree with you, other than it’s most likely more than a billion … so why do you hold capital in the company then (as a shareholder)?
You absolutely prove my point
Good luck with it
Cheers

Last edited by asxunsullied: 22/09/23

AVR Price at posting: $19.40 Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

Virgin joins Greatland, VBX Ltd as IPO market heats up ahead of FY26

CKF

Profits after tax down -88%, and shares rocket – what's going on with Collins?

SPN

Sparc opens small-scale green H2 plant in SA, but liquidity dried up

MTS

'Outperforming' Metcash books profits lift – even as illegal tobacco rocks sales

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

First 60 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $6.01		Change 0.010(0.17%)		Mkt cap ! $93.14M

Open	High	Low	Value	Volume
$6.00	$6.06	$6.00	$35.51K	5.901K

Buyers (Bids)

No.	Vol.	Price($)
2	915	$6.05

Sellers (Offers)

Price($)	Vol.	No.
$6.14	2584	2

View Market Depth

No.	Vol.	Price($)
1	15	6.050
1	77	6.010
3	541	6.000
1	600	5.950
1	25	5.850

Price($)	Vol.	No.
6.140	2584	2
6.150	218	1
6.160	20	1
6.200	1000	1
6.220	191	1

Last trade - 15.08pm 24/06/2025 (20 minute delay)

AVR (ASX) Chart

Ann: Anteris to Present at Cantor Healthcare Conference, page-60

Virgin joins Greatland, VBX Ltd as IPO market heats up ahead of FY26

Profits after tax down -88%, and shares rocket – what's going on with Collins?

Sparc opens small-scale green H2 plant in SA, but liquidity dried up

'Outperforming' Metcash books profits lift – even as illegal tobacco rocks sales

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Anteris to Present at Cantor Healthcare Conference, page-60

Top Stories

Virgin joins Greatland, VBX Ltd as IPO market heats up ahead of FY26

Profits after tax down -88%, and shares rocket – what's going on with Collins?

Sparc opens small-scale green H2 plant in SA, but liquidity dried up

'Outperforming' Metcash books profits lift – even as illegal tobacco rocks sales

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News